Amgen will have rights to research, develop, and commercialise ADCs to treat up to five targets. Credit: National Cancer Institute on Unsplash.

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC).

Under the deal terms, Amgen was granted rights for the research, development, and commercialisation of ADCs that will be directed to treat up to five targets which are chosen by the company using the ConjuAll ADC technology of LegoChem.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The clinical-stage ConjuAll ADC technology platform offers optimised site-specific conjugation, along with cancer selective linker activation as well as payload technologies for ADCs.

It also overcomes the existing traditional technologies’ limitations which produce heterogeneous ADCs with better stability, safety, and potency.

As per the terms of the agreement, LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.

The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

LegoChem Biosciences president and CEO Yong-Zu Kim said: “Amgen has a proven track record of bringing transformative medicines to market, and we are pleased that they selected our ADC technology to integrate with their efforts to develop next-generation ADCs.

“This licensing agreement demonstrates LCB’s continued recognition as an industry-leading ADC player and further enhances our ability to innovate through global partnership as we build out our pipeline and accelerate our transformation into a fully-integrated oncology company.”

Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.

Last month, LegoChem and NextCure entered into a collaboration and co-development agreement for the development of a B7-H4 ADC, and features options for two further targets.